Oct.—Oncology start-up Castle Biosciences has received an option to license a pharmacogenomics test for glioblastoma multiforme (GBM) that was developed and validated by the University of Texas's MD Anderson Cancer Center.
By examining the genetic code of the tumor, the molecular diagnostic is able to determine if a patient will respond to standard treatment for GBM: radiation plus the cytotoxic chemotherapeutic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?